Posts

Posted on

AppLovin Corporation (APP) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire


LOS ANGELES
, March 31, 2025 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with losses related to AppLovin Corporation (“AppLovin” or the “Company”) (NASDAQ: APP) have opportunity to lead the securities fraud class action lawsuit.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN APPLOVIN CORPORATION (APP), CLICK HERE BEFORE MAY 5, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

What Is The Lawsuit About? 
The complaint filed alleges that, between May 10, 2023 and February 25, 2025, Defendants failed to disclose to investors: (1) that AppLovin’s app segment relied on the systematic exploitation of fraudulent advertising practices including ‘clickjacking’ and ‘click spoofing’; (2) that AppLovin’s advertising and e-commerce program relied on intercepting and appropriating advertising attribution credit; (3) that AppLovin employed a backdoor installation scheme to force unwanted apps on customers; (4) that as a result of the foregoing, AppLovin’s revenue was falsely inflated; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz, 
Email us at: [email protected]
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.  

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/applovin-corporation-app-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302414903.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

Posted on

LINKING SECURITY: ALLEGION US FEATURES INTEROPERABILITY, MOBILE CREDENTIALS, ZENTRA AND NEW SOLUTIONS AT ISC WEST

PR Newswire

Allegion addresses the challenges of modern security with innovative products and services that link the world to seamless and secure access


LAS VEGAS
, March 31, 2025 /PRNewswire/ — Allegion US, a leading provider of security solutions, technology and services, will be exhibiting and demonstrating new interoperable electronic access control technologies and software at ISC West 2025 (booth #25053), the security industry’s most comprehensive and converged trade show occurring from March 31-April 4, 2025, at the Venetian Expo in Las Vegas.

“At Allegion, interoperability is key to our vision of providing seamless and secure access solutions,” says Mark Casey, vice president of national electronic sales at Allegion. “By fostering integration across a wide array of technologies and manufacturers, we offer users the flexibility to choose the best solutions for their specific needs. This commitment to interoperability not only simplifies and accelerates the adoption of new technologies but also empowers our customers with more choices in hardware and systems. We’re thrilled to showcase how these open architecture solutions can revolutionize access control at ISC West this year.”

Allegion’s commitment to being the partner of choice is rooted in being able to serve customers holistically – from design and collaboration tools to hardware, software and the technology relationships that ultimately give customers the freedom of choice. Through the Allegion Alliance Network, Allegion develops collaborative relationships with other companies to provide a broader range of products and services. In addition, participation with Connectivity Standards Alliance (CSA) and the FiRA consortium provides cutting-edge, cross-industry collaboration with a focus on solving for end-user needs. And new collaborations with leading companies like SwiftConnect provide customers with accelerated adoption of NFC mobile credentials and seamless access experiences.

Allegion experts, including three SIA Women in Security Power 100 honorees, will be connecting with attendees and showcasing the company’s latest products and solutions, including:

  • Schlage Mobile Credentials: Schlage offers a full portfolio of NFC credentials in Apple Wallet® and Google Wallet™ including Employee Badge, Student ID and Resident Key to provide users with high levels of convenience, enhanced security and seamless access. Now in 2025, Schlage is the first and only security solutions provider to support mobile credentials on Wear OS by Google Smartwatches. This means Schlage mobile credentials are the only solution available for iPhone® and Apple Watch as well as Android phones and Wear OS smartwatches. Allegion is proud to work collaboratively with its software alliance partners to integrate Schlage mobile credentials and access control devices into their systems, ultimately bringing an entire solution to a broader market.


  • Schlage’s New Latch Retraction Mortise Solutions
    : Six L Series mortise functions featuring ultra-quiet, motor-driven latch retraction will premiere at ISC West. Quick activation for momentary or continuous operation plus the ability to sense side load aids in overcoming static pressure and warped door conditions. Compatible with access control and fire systems, functions include passage, storeroom, institutional and electrified lever control options unique in the marketplace. These solutions can provide a more elegant and quieter solution for doors that commonly employ electric strikes. Paired with an auto operator, it is a perfect solution for accessible restrooms, hands-free and many other types of entries.


  • Von Duprin Outdoor Defense
    : The Outdoor Defense (OUT) option for Von Duprin exit devices is designed to safeguard against moisture, temperature variations, and corrosion in exterior applications. Available for the popular 98/99 Series rim and surface vertical rod exit devices, this option is engineered to protect internal components that are critical to the exit device function. The Outdoor Defense option is also available for popular electronic components, such as switches, latch retraction, delayed/controlled egress, alarm kits and more.


  • Zentra

    : Zentra™ is redefining security with a seamless solution designed to solve the everyday problems of multifamily property access. Property owners and managers can run operations efficiently on one single access system, while providing their residents with a seamless security solution across the property.

  • New ND Series Keyed Privacy Indication Trim Options: Following the 2024 introduction of Schlage’s best-in-class indication trims for mortise, cylindrical and deadbolt locks, Grade 1 cylindrical ND Series is now expanding the indication offering. Five new exterior indication options all feature keyed unlocking and the same large, 180-degree window visibility that sets these trims apart. This release also includes indication trim options for two popular entrance functions that can be applied on either the inside or the outside of the entry.


  • Overtur
    : Overtur™ is a cloud-based solution from Allegion that enables project teams to work together on the design, construction and management of door security and openings from any location. It offers a central hub to store, update and verify door hardware specifications and choices, with seamless integration with leading industry tools. Overtur also has features like Installation Status, Punch List and Site Survey that make it easier to collect and organize onsite data in one place, reducing the reliance on paper and manual processes.


  • Schlage XE360

    : Building on the innovation of Schlage electronic locks, the XE360™ Series is the next generation of wireless electronic lock from Schlage made to fit the needs of a wide range of common area openings. Its sleek design offers customers a solution that looks as good as it performs – at an affordable price point. The Schlage XE360™ Series presents multifamily property owners and managers a unique opportunity to increase operational efficiencies, drive revenue and enhance renter acquisition and retention.

Additionally, show attendees can stop by the Partner Alliance for Safer Schools (PASS) booth #10143 to learn more about Allegion’s efforts alongside PASS to improve school safety and security. Attendees can speak with on-the-floor experts to learn about how to help schools implement PASS Guidelines and avoid critical security mistakes.

Security professionals who will not be attending the show in person this year can utilize Allegion’s online resources including the Changing Face of School Security Podcast, the Solving for Multifamily Podcast, and a wide array of Virtual Trainings. 

For more information, please visit us.allegion.com.

About Allegion 

At Allegion (NYSE: ALLE), we design and manufacture innovative security and access solutions that help keep people safe where they live, learn, work and connect. We’re pioneering safety with our strong legacy of brands like CISA®, Interflex®, LCN®, Schlage®, SimonsVoss® and Von Duprin®. Our comprehensive portfolio of hardware, software and electronic solutions is sold around the world and spans residential and commercial locks, door closer and exit devices, steel doors and frames, access control and workforce productivity systems. For more, visit www.allegion.com.  

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/linking-security-allegion-us-features-interoperability-mobile-credentials-zentra-and-new-solutions-at-isc-west-302414954.html

SOURCE Allegion US

Posted on

Pearson Announces Newly Expanded Role for Chief Technology Officer, Dave Treat, as Company Further Scales AI and Tech Capabilities

PR Newswire


  • Dave Treat to lead Pearson’s digital and technology operation, expanding his current architectural and innovation responsibilities


LONDON
, March 31, 2025 /PRNewswire/ — Pearson (FTSE: PSON.L), the world’s lifelong learning company, announced today that Dave Treat, Pearson’s Chief Technology Officer, will assume leadership of the company’s digital and technology operation alongside his current architectural and innovation responsibilities, effective April 7. Dave will continue to report to CEO Omar Abbosh and retain his title of Chief Technology Officer. Marykay Wells, who has led the Digital and Technology team as Chief Information Officer, has decided to leave Pearson, effective April 4.  

Dave joined Pearson nine months ago and spearheaded the establishment of the company’s AI Center of Enablement, while also overseeing the Research & Development and Ventures teams. He brings to the role nearly 30 years of experience, with deep expertise in technology innovation, generative AI, spatial computing, Web 3, and quantum computing. Prior to joining Pearson, Dave held several senior technology roles at Deloitte, UBS Investment Bank, and Accenture. He holds more than 100 patents in distributed ledger technology, digital identity, and confidential computing. He also lends his expertise as an active member of CNBC’s Technology Executive Council, the World Economic Forum’s Global Futures Council on Financial Education, and as a member of the transitional board of Arya. 

With his extensive expertise, Dave will play a crucial role in leveraging Pearson’s strong technology foundation to scale the company’s AI offerings, bolster its innovation pipeline, and improve collaboration across different business units.  


Omar Abbosh, Pearson CEO, said: “Dave has had a significant influence on Pearson in the nine short months since he joined the company. His innovative work with customers is already positioning us for stronger growth. Through his leadership in developing our innovation architecture and establishing our AI Center, he has been a key player in our ability to attract and harness the incredible talent and capabilities of Pearson. He also is inspiring our team to envision the next big breakthrough. 

“We have been very lucky to have Marykay at the helm of our technology efforts in recent years. Her strategic and disciplined leadership drove a massive and complex print-to-digital transformation. She and her global team embraced generative AI to build state-of-the-art global platforms and solutions to drive efficiency, simplicity, and productivity, while creating improved customer experiences. I want to thank Marykay for transforming our technology foundations and capabilities.” 


Dave Treat, Chief Technology Officer, said: “Being part of Pearson at this thrilling juncture for the company is a source of pride for me, especially as technology begins to revolutionize how we learn and work. What Marykay and the digital and technology organization have accomplished over the years to modernize and expand our technology estate – especially with generative AI – is truly amazing. I am eager to take that work forward and explore new ways to leverage innovative technology to help people realize the life they imagine through learning.” 

Dave has helped to found and has served on several technology and industry boards including the Linux Hyperledger Foundation, Linux Open Wallet Foundation, Digital Dollar Project and the Global Business Blockchain Council.  

Dave earned a Master’s degree in Higher Education Administration from the University of Michigan and a degree in Psychology from the University of Pennsylvania. He will continue to be based in Connecticut, USA. 

About Pearson
At Pearson, our purpose is simple: to help people realize the life they imagine through learning. We believe that every learning opportunity is a chance for a personal breakthrough. That’s why our c. 18,000 Pearson employees are committed to creating vibrant and enriching learning experiences designed for real-life impact. We are the world’s lifelong learning company, serving customers in nearly 200 countries with digital content, assessments, qualifications, and data. For us, learning isn’t just what we do. It’s who we are. Visit us at pearsonplc.com. 

Media Contacts


[email protected]
 – US 
[email protected] – UK 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/pearson-announces-newly-expanded-role-for-chief-technology-officer-dave-treat-as-company-further-scales-ai-and-tech-capabilities-302415819.html

SOURCE Pearson

Posted on

Albertsons® Companies Launches Over 20 Limited Edition Own Brands Products to Celebrate the Spring Season

Albertsons® Companies Launches Over 20 Limited Edition Own Brands Products to Celebrate the Spring Season

Lemon-inspired snacks, sweets, drinks and fresh food items feature a citrusy “Burst of Flavor”

BOISE, Idaho–(BUSINESS WIRE)–
Albertsons® Companies, Inc. (NYSE: ACI) today unveiled a new limited edition collection of lemon-inspired Own Brands products to celebrate the arrival of spring. Available now through May 9, customers will find delicious lemony candy, cookies, pretzels, chips, popcorn, sparkling water and more from the grocer’s private label brands Signature SELECT®, Overjoyed™ and Soleil®. Presented in vibrant, unified packaging across brands, these spring products are promoted through a zesty “Burst of Flavor” marketing campaign and available online and in Albertsons Cos. stores including Albertsons, Safeway, ACME, Jewel-Osco, Shaw’s, Vons and Tom Thumb.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250331952186/en/

Albertsons Companies, Inc. unveiled a new limited edition collection of lemon-inspired Own Brands products to celebrate the arrival of spring. Courtesy: Albertsons Companies

Albertsons Companies, Inc. unveiled a new limited edition collection of lemon-inspired Own Brands products to celebrate the arrival of spring. Courtesy: Albertsons Companies

“At Albertsons Cos., we put our customers at the center of everything we do to create Customers for Life,” said Omer Gajial, EVP of Merchandising and Chief Digital Officer at Albertsons Cos. “By investing in our Own Brands and introducing innovative products, we’re adding value and excitement for our customers. This spring, our new Own Brands lemon-inspired offerings add variety and novelty to our customers’ weekly shopping routines, inspiring them to explore and try new products and create new moments of delight.”

The lemon-inspired products can be found across store departments including bakery, deli, frozen and floral. Shoppers will be enticed by a delightful array of citrusy treats from Overjoyed, featuring lemon flavored wafer rolls, mini cookies, sandwich sugar cookies and madeleines. For those seeking a fun afternoon snack, the Signature SELECT brand boasts new flavors including Lemon Potato Chips, Lemon Pepper Cashews and Raspberry Lemon Crispy Rice Treats. For a refreshing experience, Soleil offers two exciting new sparkling water flavors to satisfy any thirst.

Promoted via the company’s email, social and digital channels as well as in-store signage and weekly print ads, the “Burst of Flavor” marketing campaign features a vibrant and energetic color palette, spotlighting the star ingredient – lemon – alongside a medley of other juicy fruits.

Looking ahead,Albertsons Cos. is also planning exciting seasonal programs for the fall and winter, each with a festive twist.

Albertsons Cos.’ Own Brands portfolio includes trusted household names such as Signature SELECT, Overjoyed, O Organics®, Open Nature®, Lucerne®, Primo Taglio®, waterfront BISTRO®, Soleil and Value Corner®. Shoppers can find Own Brands products exclusively at Albertsons Cos. stores.

To download high-res images, please click here.

About Albertsons® Companies, Inc.

Albertsons is a leading food and drug retailer in the United States. As of November 30, 2024, the Company operated 2,273 retail food and drug stores with 1,732 pharmacies, 405 associated fuel centers, 22 dedicated distribution centers and 19 manufacturing facilities. The Company operates stores across 34 states and the District of Columbia under more than 20 well known banners including Albertsons, Safeway, Vons, Jewel-Osco, Shaw’s, ACME, Tom Thumb, Randalls, United Supermarkets, Pavilions, Star Market, Haggen, Carrs, Kings Food Markets and Balducci’s Food Lovers Market. In 2023, along with the Albertsons Companies Foundation, the Company contributed more than $350 million in food and financial support, including more than $35 million through our Nourishing Neighbors Program to ensure those living in our communities and those impacted by disasters have enough to eat.

Media Contact: [email protected]

KEYWORDS: United States North America Idaho

INDUSTRY KEYWORDS: Food/Beverage Online Retail Discount/Variety Retail Supermarket

MEDIA:

Photo
Photo
Albertsons Companies, Inc. unveiled a new limited edition collection of lemon-inspired Own Brands products to celebrate the arrival of spring. Courtesy: Albertsons Companies
Photo
Photo
Albertsons Companies, Inc. unveiled a new limited edition collection of lemon-inspired Own Brands products to celebrate the arrival of spring. Courtesy: Albertsons Companies
Logo
Logo
Posted on

Kinepolis and IMAX® Expand Global Partnership with Multi-Territory Agreement for Nine New IMAX Locations across Europe and North America

Kinepolis and IMAX® Expand Global Partnership with Multi-Territory Agreement for Nine New IMAX Locations across Europe and North America

On the Eve of Blockbuster Season, Kinepolis Commits to New IMAX Locations in France, Spain, Belgium and The Netherlands, as well as the U.S. and Canada

LAS VEGAS–(BUSINESS WIRE)–
On the eve of global blockbuster season, Kinepolis and IMAX Corporation (NYSE: IMAX) today announced a multi-territory expansion of their longstanding global partnership with nine new state-of-the-art IMAX® with Laser systems across Europe, the U.S., and Canada. Under the agreement, Kinepolis will almost double the size of its IMAX offering in Europe to 13 locations, with seven new locations across France (1), Belgium (1), Spain (2), and the Netherlands (3). The agreement will also see Kinepolis add new IMAX locations in the United States and Canada.

The announcement was made today at CinemaCon 2025 in Las Vegas, as IMAX concludes a strong first quarter at the global box office and enters a summer blockbuster season with more Filmed for IMAX releases than ever, including the forthcoming “Sinners,” “Thunderbolts,” “Mission: Impossible – The Final Reckoning,” “How to Train Your Dragon,” “Superman,” and “The Fantastic Four.”

The agreement builds on a previous deal signed with Kinepolis in 2023 for eight IMAX locations, almost all of which were installed the same year. Inclusive of this deal, IMAX has tripled their network with the Belgium-based international exhibitor since early 2023. At present, IMAX partners with Kinepolis on twelve locations currently in operation across Belgium, France, Spain, Luxembourg, the U.S. and Canada.

“We are dedicated to providing premium cinema experiences that cater to the growing demand for richer and more immersive moviegoing. Our commitment is to deliver the best possible film experience for each movie, and IMAX has consistently proven its ability to elevate the viewing experience of Hollywood’s biggest films. We are thrilled to expand our IMAX footprint and bring this exceptional experience to even more audiences,” said Eddy Duquenne, CEO of Kinepolis Group.

“As we close out a strong quarter for system sales and enter a blockbuster season full of films made to be seen in IMAX, it is clear that demand for our platform is growing,” said Rich Gelfond, CEO of IMAX. “Kinepolis is a world-class global exhibitor with a first-rate management team, beautiful cinemas, and excellent locations, and we look forward to expanding further across its global footprint.”

Under the terms of the deal, eight of the new locations will open before the end of 2025. This will also mark the first time Kinepolis and IMAX have partnered on locations in the Netherlands and will double our network with MJR Cinemas in Michigan.

The deal was established with Kinepolis and their wholly owned subsidiaries, MJR Theatres and Landmark. MJR Theatres operates locally in the Metro Detroit area in Michigan, while Landmark operates theatres across several provinces in Canada.

The nine new locations for Kinepolis and its subsidiaries will be equipped with IMAX with Laser, IMAX’s most advanced entertainment experience. Immersive by design, IMAX with Laser has been developed from the ground-up to deliver crystal clear, lifelike images and precision audio for a moviegoing experience unlike anything else. The experience is set apart by a ground-breaking 4k laser projection system that features a new optical engine, custom designed lenses, and a suite of proprietary technology that delivers brighter images with increased resolution, deeper contrast, and the widest range of colors exclusively to IMAX screens.

About IMAX Corporation

IMAX, an innovator in entertainment technology, combines proprietary software, architecture, and equipment to create experiences that take you beyond the edge of your seat to a world you’ve never imagined. Top filmmakers and studios are utilizing IMAX systems to connect with audiences in extraordinary ways, making IMAX’s network among the most important and successful theatrical distribution platforms for major event films around the globe.

IMAX is headquartered in New York, Toronto, and Los Angeles, with additional offices in London, Dublin, Tokyo, and Shanghai. As of December 31, 2024, there were 1,807 IMAX systems (1,735 commercial multiplexes, 11 commercial destinations, 61 institutional) operating in 90 countries and territories. Shares of IMAX China Holding, Inc., a subsidiary of IMAX Corporation, trade on the Hong Kong Stock Exchange under the stock code “1970”.

IMAX®, IMAX® 3D, Experience It In IMAX®, The IMAX Experience®, DMR®, Filmed For IMAX®, IMAX LIVE™, and IMAX Enhanced® are trademarks and trade names of IMAX Corporation or its subsidiaries that are registered or otherwise protected under laws of various jurisdictions. For more information, visit www.imax.com. You may also connect with IMAX on Instagram (www.instagram.com/imax), Facebook (www.facebook.com/imax), LinkedIn (www.linkedin.com/company/imax), X (www.twitter.com/imax), and YouTube (www.youtube.com/imaxmovies).

Investors:

Jennifer Horsley

[email protected]

Media:

Mark Jafar

[email protected]

KEYWORDS: United States France Canada North America Spain Europe Netherlands Nevada

INDUSTRY KEYWORDS: Software Other Entertainment Audio/Video Film & Motion Pictures Hardware General Entertainment Technology Entertainment

MEDIA:

Posted on

​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial

​New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care

WILMINGTON, Del.–(BUSINESS WIRE)–
Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo.1,2 AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite standard-of-care-lipid lowering therapies such as statins.1,2

These new data were presented today at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo in Chicago, Illinois, US and published simultaneously in JACC.1,2

At 12 weeks, AZD0780 30mg taken once-daily (when added to the standard-of-care statin therapy and administered without any fasting or food restrictions) led to a 50.7% reduction in LDL-C [95% CI: -59.0%, -42.4%, p<0.001]. Similar efficacy was observed regardless of whether trial participants received moderate- or high- intensity statin doses at baseline.1,2 In addition, AZD0780 30mg enabled 84% [95%CI: 74.4%-90.7%] of trial participants to meet their American Heart Association/American College of Cardiology guideline-recommended LDL-C target (<70 mg/dL), compared to 13% [95%CI: 7.2%-22.3%] of participants on background statin therapy alone.1,2

High LDL-C (≥70 mg/dL), a common type of dyslipidemia, is a key risk factor for atherosclerotic cardiovascular disease, including stroke and heart attack, and a significant public health concern.3 It is estimated that more than 70% of patients worldwide are currently not reaching guideline-recommended LDL-C targets.4-7

Dr. Michael J Koren, MD, CEO & Medical Director of Jacksonville Center for Clinical Research, Florida, US and PURSUIT Principal Investigator, said: “The PURSUIT Phase IIb trial demonstrates the potential of AZD0780 to provide a much-needed once-daily oral treatment option to deliver greater LDL cholesterol lowering on top of standard of care for millions of patients who remain at risk for serious cardiovascular events including premature death. These results are particularly important because the majority of patients with atherosclerotic disease today do not reach their LDL-C goals, despite availability of lipid-lowering therapies such as statins and injectable PCSK9 inhibitors.”

Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “These new data reflect AZD0780’s ability to reduce LDL cholesterol in patients who need more options to manage their cholesterol and related risks when standard-of-care therapy is not enough. As a novel small molecule oral PCSK9 inhibitor that can be taken without fasting restrictions, AZD0780 has the potential to be a game changer that could offer LDL-C lowering with greater convenience for patients. Our work in dyslipidemia builds on our strong heritage in cardiovascular, renal and metabolic diseases where we are advancing novel therapies, alone or in combination with other molecules in our extensive portfolio, that could redefine treatment standards and patient outcomes.”

AZD0780 was generally well tolerated, and adverse events (AEs) were comparable between the total AZD0780 treatment groups (38.2%) and placebo (32.6%).1,2 The frequency of treatment discontinuations due to AEs was similar across AZD0780 (1.5%) and placebo (2.3%) groups.1,2

Data from PURSUIT are consistent with Phase I findings presented at European Atherosclerosis Society (EAS) 2024.8

Notes

About Dyslipidemia

Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 4.4 million deaths worldwide annually.3 Despite current treatment options, the global burden of dyslipidemia is on the rise.4 More than 70% of patients with atherosclerotic cardiovascular disease (ASCVD) are still not achieving their LDL-C target, so there remains a vast unmet need among high-risk patients for more varied and effective treatment options.4-7

PURSUIT

PURSUIT is a Phase IIb, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy, safety and tolerability of AZD0780 in participants with dyslipidemia.2

PURSUIT assessed the efficacy, safety and tolerability of different doses of AZD0780 on LDL-C levels in patients with hypercholesterolemia. 428 patients on stable standard-of-care therapy with moderate- or high-intensity statins with or without ezetimibe with LDL-C levels ≥70 and <190 mg/dL were randomized (1:1:1:1:1) to receive AZD0780 (1 mg, 3 mg, 10 mg and 30 mg daily) or matching placebo. 426 patients started treatment.2

The primary objective of the study was to measure the effect of different doses of AZD0780 given once daily on LDL-C levels in patients with dyslipidemia receiving standard-of-care statins. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers was also investigated. The concentration of AZD0780 in blood at specific timepoints was measured, and the safety and tolerability of AZD0780 evaluated.2

AZD0780

AZD0780 is an oral, small molecule PCSK9 inhibitor that is being developed by AstraZeneca as an innovative therapy for patients with elevated low-density lipoprotein cholesterol (LDL-C) levels which cannot be controlled by statins alone.2 PCSK9 is a well-known and validated target in LDL-C metabolism and inhibiting PCSK9 signalling has shown to be effective in reducing LDL-C levels in plasma.2 Lower LDL-C levels are associated with a reduction in the risk of long-term cardiovascular disease and major cardiovascular events.9 AstraZeneca is investigating the potential of AZD0780 as an oral small-molecule for use as a monotherapy or in fixed-dose combinations with other therapies in our extensive portfolio. Data from PURSUIT are consistent with Phase I findings for AZD0780 which demonstrated a statistically significant reduction of 51% in LDL-C levels on top of rosuvastatin treatment, with 80% total reduction from baseline, in treatment-naive participants with hypercholesterolemia.2

AstraZeneca in CVRM

Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca’s main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way towards regenerative therapies. The Company’s ambition is to improve and save the lives of millions of people, by better understanding the interconnections between CVRM diseases and targeting the mechanisms that drive them, so we can detect, diagnose and treat people earlier and more effectively.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 125 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on social media @AstraZeneca.

References

  1. Koren M, et al. Efficacy and safety of AZD0780, an oral small molecule PCSK9 inhibitor for treatment of hypercholesterolemia: Results from a Ph2b randomized placebo-controlled clinical trial. Presented at: American College of Cardiology Annual Scientific Session (ACC 2025); 2025 Mar 29-31; Chicago, IL.
  2. Koren MJ, et al. An oral, small molecule PCSK9 inhibitor for treatment of hypercholesterolemia: the PURSUIT randomized trial. J Am Coll Cardiol. 2025.
  3. World Heart Federation. Cholesterol. Available at: https://world-heart-federation.org/what-we-do/cholesterol/#:~:text=High%20blood%20cholesterol%20is%20one,or%207.8%25%20of%20all%20deaths [Last accessed: March 2025].
  4. Pirillo A, et al. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689-700.
  5. Cannon CP, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6:1060-1068.
  6. Ray KK, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624.
  7. Underberg J, et al. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgrad Med. 2022;134:752-762.
  8. Vega R, et al. AZD0780, the first oral small molecule PCSK9 inhibitor for the treatment of hypercholesterolemia: results from a randomized, single-blind, placebo-controlled phase 1 trial. Atherosclerosis. 2024;395:118514.
  9. Domanski MJ, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76(13):1507-1516.

Media Inquiries

Fiona Cookson +1 212 814 3923

Chelsea Tressler +1 302 885 2677

US Media Mailbox: [email protected]

KEYWORDS: United States North America Delaware

INDUSTRY KEYWORDS: Health Clinical Trials General Health Pharmaceutical Cardiology Biotechnology

MEDIA:

Logo
Logo
Posted on

Forge Global Announces Reverse Stock Split

Forge Global Announces Reverse Stock Split

SAN FRANCISCO–(BUSINESS WIRE)–
Forge Global Holdings, Inc. (“Forge,” or the “Company”) (NYSE: FRGE), a leading global private securities marketplace, today announced that its Board of Directors approved a 1-for-15 reverse stock split of its Common Stock to be effective 12:01 a.m., Eastern Time, on April 14, 2025. The Company expects its Common Stock to begin trading on a split-adjusted basis on the New York Stock Exchange as of the commencement of trading on April 15, 2025.

On March 27, 2025, the Company’s stockholders approved a reverse stock split of the Company’s Common Stock at a ratio ranging from 1-for-3 to 1-for-50, inclusive, with such ratio to be determined at the discretion of the Company’s Board of Directors and with such reverse stock split to be effected at such time and on such date as determined by the Board of Directors in its sole discretion (but in no event later than March 27, 2026). The reverse stock split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on the New York Stock Exchange.

The 1-for-15 reverse stock split will automatically result in the conversion of fifteen (15) current shares of the Company’s Common Stock into one (1) new share of Common Stock. The Company’s Common Stock will continue to trade on the New York Stock Exchange under the symbol “FRGE” following the reverse stock split, with a new CUSIP number of 34629L 202. No fractional shares will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to a fractional share will receive cash equal to the fair market value of the fractional share, determined by multiplying such fraction by the closing sales price of our Common Stock as reported on the New York Stock Exchange on April 11, 2025 (as adjusted to give effect to the reverse stock split). Proportional adjustments will also be made to the number of shares of Common Stock awarded and available for issuance under the Company’s equity incentive plans, as well as the exercise price and the number of shares issuable upon the exercise or conversion of the Company’s outstanding stock options, restricted stock units and other equity securities under the Company’s equity incentive plans. Additionally, all outstanding warrants will be adjusted in accordance with their terms, which will, among other changes to the warrant terms, result in proportionate adjustments being made to the number of shares issuable upon exercise of such warrants and to the exercise prices of such warrants.

Continental Stock Transfer & Trust Company (“Continental”), the Company’s transfer agent, is acting as the exchange agent for the reverse stock split. Stockholders of record owning their shares in book-entry will be receiving a transaction statement from Continental regarding their Common Stock ownership post-reverse stock split and are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, custodian or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to the holding entity’s particular processes; such stockholders will not be required to take any action to receive post-split shares. However, these banks, brokers, custodians or other nominees may have different procedures than Continental for processing the reverse stock split. If a stockholder holds shares of Common Stock with a bank, broker, custodian or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker, custodian or other nominee for more information.

Additional information about the reverse stock split can be found in the Company’s definitive proxy statement (the “Proxy Statement”) filed with the Securities and Exchange Commission (the “SEC”) on February 27, 2025, which is available at the SEC’s website, www.sec.gov, and on the Company’s website at https://ir.forgeglobal.com/financials/sec-filings.

About Forge

Forge (NYSE: FRGE) is a leading provider of marketplace infrastructure, data services and technology solutions for private market participants. Forge Securities LLC is a registered broker-dealer and a Member of FINRA that operates an alternative trading system.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “strategy,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “opportunity” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although Forge believes that it has a reasonable basis for each forward-looking statement contained in this press release, Forge cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which it cannot be certain. Forward-looking statements in this press release include, but are not limited to, Forge’s expectations regarding the effect of the reverse stock split, its ability to maintain its listing on the New York Stock Exchange, and the actions of third parties, including Continental, with respect to the reverse stock split. The forward-looking statements contained in this press release are subject to risks and uncertainties, which may cause the actual outcomes or results to vary from those indicated by the forward-looking statements. These risks and uncertainties include market conditions and their impact on the trading price of Forge’s Common Stock on the New York Stock Exchange, and other risks and uncertainties, including those more fully described in the Proxy Statement and Forge’s Annual Report on Form 10-K filed with the SEC on March 6, 2025, and other risks and uncertainties detailed from time to time in Forge’s filings with the SEC. Forge undertakes no obligation to revise or update publicly any forward-looking statements except as required by law.

Investor Relations Contact

Dominic Paschel

[email protected]

Media Contact

Lindsay Riddell

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Sports Networks Finance Sailing Data Management Professional Services Technology Other Technology

MEDIA:

Logo
Logo
Posted on

Wolf Haldenstein informs investors that Zynex, Inc. has been sued

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit was filed against Zynex, Inc. (NASDAQ: ZYXI) on behalf of shareholders who purchased stock between March 13, 2023, and March 11, 2025, inclusive.


CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION AND JOIN THE CASE

  • Lead Plaintiff Deadline: May 19, 2025.

  • Allegations:

    • Zynex shipped products, including electrodes, beyond what customers actually needed.
    • This practice inflated the company’s revenue.
    • The company allegedly filed false claims, which drew scrutiny from insurers, including Tricare.
    • As a result, Zynex faced the risk of removal from insurer networks and potential federal penalties.
    • The company’s positive statements about its business and prospects were allegedly misleading or lacked a reasonable basis.

Wolf Haldenstein has experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago, Nashville and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

Contact Information:

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.



Posted on

Allstate to Hold Q1 2025 Earnings Call May 1

Allstate to Hold Q1 2025 Earnings Call May 1

NORTHBROOK, Ill.–(BUSINESS WIRE)–
The Allstate Corporation (NYSE: ALL) will host a conference call and webcast at 9 a.m. ET on Thursday, May 1, 2025, to discuss first-quarter 2025 financial results.

Allstate plans to file its results via a Form 8-K with the Securities and Exchange Commission (SEC) after 4:15 p.m. ET on Wednesday, April 30. The earnings release and investor supplement will be accessible shortly after filing on the SEC’s website (www.sec.gov) and Allstate’s Investor Relations website (www.allstateinvestors.com).

Get Allstate financial news at www.allstateinvestors.com:

  • View the Form 8-K, earnings release and investor supplement after filing.
  • Join the live conference call and access the webcast replay, which will be posted shortly after the call concludes.
  • Stay informed on financial news and material announcements by subscribing to Allstate’s email alerts and RSS feeds, via the “Email Alerts” section on the site.
  • Plan for future earnings calls and webcasts with preliminary dates and times.

About Allstate

The Allstate Corporation (NYSE: ALL) protects people from life’s uncertainties with a circle of protection including cars, homes, electronic devices, benefits and identity theft. Products are available through a broad distribution network including Allstate agents, independent agents, major retailers, online and at the workplace. Allstate is widely known for the slogan “You’re in Good Hands with Allstate.” Financial information, including material announcements about The Allstate Corporation, is routinely posted on www.allstateinvestors.com.

Nick Nottoli

(847) 402-5600

Allister Gobin

(847) 402-2800

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Other Professional Services Professional Services Insurance Finance

MEDIA:

Logo
Logo
Posted on

Check Point Software Emerges as a Leader in Attack Surface Management After Acquiring Cyberint, According to Latest GigaOm Radar Report

Cyberint, rebranded as Check Point External Risk Management, offers a comprehensive view of an organization’s cyber threats across the open, deep, and dark web

REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) — Check Point Software Technologies Ltd. (NASDAQ: CHKP), a pioneer and global leader of cyber security solutions, has emerged as a leading player in Attack Surface Management (ASM) with its acquisition of Cyberint, as highlighted in the recent GigaOm Radar report. Cyberint, recognized as a top performer in the Maturity/Platform Play quadrant, now brings its ASM expertise to Check Point’s External Risk Management solution. This combination of automated asset discovery and continuous risk monitoring with advanced threat intelligence provides customers with superior attack surface oversight and enhanced security measures.

According to Gartner, “by 2026, organizations that prioritize their security investments based on a continuous exposure management program will be 3X less likely to suffer a breach,” highlighting the need for a strong ASM solution. The GigaOm Radar for Attack Surface Management assessed 29 leading ASM solutions, with analyst Chris Ray highlighting Cyberint’s performance. According to Ray, “Cyberint achieved its Outperformer status thanks to its innovative approach to threat intelligence and robust integration capabilities. The company’s continuous improvement of core features, along with an expanded scope of threat intelligence and more accurate alerts, positions it for significant market growth in the coming years.”

As part of the Check Point Infinity Platform, the External Risk Management solution equips organizations with proactive security capabilities to effectively oversee their attack surface. By merging ongoing asset discovery, cutting-edge threat intelligence, and AI-powered prevention, this solution delivers real-time visibility and automated risk mitigation, integrating smoothly with the Check Point portfolio.

“We are proud to be recognized as a leader in this space,” said Yochai Corem, VP of External Risk management at Check Point Software Technologies. “Our leadership shows how our customers can benefit from a comprehensive external view mapped to the threats related to their assets and the ability to simplify the remediation to those threats.”

With cyber threats evolving at an unprecedented pace, Check Point’s approach ensures organizations can stay ahead of adversaries, reduce exposure, and enhance their overall security posture with ease. Other standout features highlighted in GigaOm’s evaluation include:

  • Augmented Threat Visibility: Continuous and autonomous scanning of the entire modern attack surface including IP, Domains, third party, dark web and more
  • Proactive Security Validation: Passive attack surface discovery combined with active exposure validation. This proactive scanning capability tests the exploitability of vulnerabilities and exposures on internet-facing assets so customers can quickly identify and remediate imminent risks
  • Advanced Threat Intelligence: Through Check Point ThreatCloud AI, the platform provides a combined view, facilitating rapid, real-time threat intelligence sharing, enhancing the speed and effectiveness of threat detection and response

Discover additional details about this award on our blog and access a free copy of the GigaOm Radar for Attack Surface Management here.

Follow Check Point via:

X (Formerly known as Twitter): https://www.twitter.com/checkpointsw
Facebook: https://www.facebook.com/checkpointsoftware
Blog: https://blog.checkpoint.com
YouTube: https://www.youtube.com/user/CPGlobal
LinkedIn: https://www.linkedin.com/company/check-point-software-technologies

About Check Point Software Technologies Ltd. 

Check Point Software Technologies Ltd. (www.checkpoint.com) is a leading AI-powered, cloud-delivered cyber security platform provider protecting over 100,000 organizations worldwide. Check Point leverages the power of AI everywhere to enhance cyber security efficiency and accuracy through its Infinity Platform, with industry-leading catch rates enabling proactive threat anticipation and smarter, faster response times. The comprehensive platform includes cloud-delivered technologies consisting of Check Point Harmony to secure the workspace, Check Point CloudGuard to secure the cloud, Check Point Quantum to secure the network, and Check Point Infinity Platform Services for collaborative security operations and services.

MEDIA CONTACT: INVESTOR CONTACT:
Ana Perez Kip E. Meintzer
Check Point Software Technologies Check Point Software Technologies 
[email protected] [email protected]